Introduction
Orysastrobin was discovered and patented by BASF Aktiengesellschaft in 1995. In experiments conducted by a large number of agricultural research organizations, this strobilurin compound has been shown to be highly effective against two major diseases of rice plants, blast (Magnaporthe grisea) and shealth blight (Thanatephorus cucumeris) both in rice nursery box treatment and granular treatment of an established rice crop. Orysastrobin is systemic in action (which enables easy field application) and has long residual activity that reduces the number of applications at later stages of rice growth. Safety studies were initiated in 1998. This paper summarizes the main results of these studies.
Subacute Neurotoxicity Study and Subchronic Toxicity Studies
A subacute oral (dietary admixture) neurotoxicity study was performed in rats. Subchronic oral (dietary admixture) toxicity studies were performed in rats and dogs. The results of these studies are summarised in Table 2 . No neurotoxicity was observed in rats at dose levels up to 3000 ppm in the diet in the 28-day neurotoxicity study. The 90-day rat study revealed reduced body weight gain and food consumption at 3000 ppm, alterations in some clinical-chemical parameters at 1000 ppm, a microcytic hypochromic anemia characteristic of iron deficiency at 3000 ppm in females, centrilobular hepatocellular hypertrophy at 3000 ppm in males, diffuse hepatocellular hypertrophy at 1000 ppm in females, thickening of duodenal mucosa at 300 ppm (which was later shown to reflect an attempt to enhance iron absorption), eosinophilic droplets in proximal renal tubules at 3000 ppm in males, and pigment deposits in proximal renal tubules at 3000 ppm. Based on thickening of duodenal mucosa, the 90-day rat study failed to establish a no observed adverse effect level (NOAEL). A supplemental 90-day rat study established the NOAEL as 100 ppm, equivalent to an average daily test article consumption of 6.8 and 8.3 mg/kg body weight for males and females, respectively. The extent of duodenal thickening is shown in Figs. 1 and 2 . Treatment-related effects in the 90-day dog study were confined to the high dose level of 1500 ppm and consisted of vomiting in weeks 1 and 2, reduced body weight gain in females, decreased serum albumin, globulin and cholesterol in males, and increased serum chloride in both sexes; the NOAEL was 500 ppm, equivalent to an average daily test article consumption of 27.5 and 35.6 mg/kg body weight for males and females, respectively.
Chronic Toxicity and Carcinogenicity Studies
Chronic toxicity and carcinogenicity were assessed in a combined chronic toxicity/carcinogenicity study in rats, a carcinogenicity study in mice, and a chronic toxicity study in dogs. The results of these studies are summarised in Table 3 .
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Thickening of duodenal mucosa at Ն500 ppm
Carcinoma and/or adenoma in the duodenum at 2500 ppm weight gain and food consumption at 2500 ppm, iron defiency anemia (microcytic anemia) at 500 ppm in males and 2500 ppm in females, an increased incidence of foci of cellular alteration in the liver at 500 ppm in males, chronic nephropathy and pyelonephritis at 2500 ppm in females, thickening of duodenal mucosa at 500 ppm, thyroid follicular cell hyperplasia at 500 ppm in males and 2500 ppm in females, and focal hyperplasia of the pars distalis in the pituitary at 2500 ppm in females. The NOAEL was 100 ppm, equivalent to an average daily test article consumption of 5.2 and 6.8 mg/kg body weight for males and females, respectively. Tumorigenic effects were noted only at 2500 ppm in the duodenum (carcinomas and/or adenomas) and in the male thyroids (follicular cell adenomas).
The main treatment-related effects in the carcinogenicity study in mice were reduced body weight gain at 2000 ppm and an increased incidence of thickening of duodenal mucosa at 2000 ppm in males, focal hyperplasia in the pylorus (at the transition of the glandular stomach to duodenum) at 500 ppm in females, centrilobular hepatocellular hypertrophy at 2000 ppm in males, and peripheral hepatocellular hypertrophy, bile duct proliferation and eosinophilic crystalline inclusions in the gall bladder at 2000 ppm in females. The NOAEL was 100 ppm, equivalent to an average daily test article consumption of 26.0 and 34.2 mg/kg body weight for males and females, respectively. Carcinogenic effects were noted at 2000 ppm in the duodenum (adenocarcinomas).
Treatment-related effects in the chronic toxicity study in dogs were confined to the high dose level of 1500 ppm for females and 1600 ppm for males, and consisted of vomiting on days 0 and 3, reduced body weight gain and food consumption, decreased serum total protein and albumin in males, and slightly higher liver weights in males and females; the NOAEL was 400 ppm, equivalent to an average daily test article consumption of 10.8 and 11.1 mg/kg body weight for males and females, respectively.
Mechanistic Studies on Carcinogenic Effects
A number of studies were performed in rats to elucidate the mechanism of carcinogenic action. The results of these studies are summarised in Table 4 . With respect to the duodenum, the carcinogenic dose level of 2500 ppm was shown to cause increased epithelial cell proliferation in the duodenal mucosa after 4 weeks, and decreased serum iron levels, increased serum transferrin levels and unsaturated iron capacity after 1 week. Based on the results of these studies, the carcinogenic effect in the duodenum was considered to be secondary to increased proliferation of the epithelium of duodenal mucosa (presumably caused by an attempt to increase iron absorption from the gastro-intestinal tract in order to compensate for the markedly decreased serum iron levels). Studies in which rats were treated with an iron-deficient diet have shown that this treatment results in similar duodenal changes. [1] [2] [3] A mechanistic study in mice also established increased proliferation of the epithelium of duodenal mucosa after 4 weeks at the carcinogenic dose of 2000 ppm, demonstrating that the same mechanism occurs in this species.
Concerning thyroid adenomas at 2500 ppm, decreased serum thyroxine (T 4 ) levels in males after 3 days, increased serum TSH (thyroid stimulating hormone) levels in males and females after 17 weeks, increased follicular cell proliferation in the thyroid in males and females after 17 weeks, increased 125 I uptake by the thyroid for males after 1 week, and increased p-nitrophenol-glucuronyltransferase (pNP-GT) activities in the liver in females after 4 weeks were observed. The carcinogenic effect in the thyroid was considered to be secondary due to TSH-induced increased proliferation of follicular cells in order to compensate for enhanced T 4 turnover caused by the induction of thyroxine-glucuronyltranferase activity in the liver. This mode of action is considered to be not relevant to humans due to the selective sensitivity of rats. [4] [5] [6] The critical effects on the duodenum and thyroid were shown to be reversible and showed a clear NOAEL of 100 ppm.
Reproduction Toxicity and Teratogenicity Studies
A two-generation oral (dietary admixture) reproduction toxicity study was performed in Wistar rats. The results of this study are summarised in Table 5A . Treatment-related findings at 1500 ppm in the parental F 0 and F 1 generations consisted of reduced body weight gain and food consumption and microcytic hypochromic anemia. In addition, centrilobular hepatocellular hypertrophy was observed at 500 ppm in parent females. Treatment-related findings at 1500 ppm in F 1 and F 2 progeny consisted of retarded growth, delayed sexual maturation (preputial separation/vaginal opening), and reduced weights of the brain, thymus, and spleen. In addition, F 2 offspring showed reduced thymus weights at 500 ppm. The reduction in organ weight and particularly delayed sexual maturation are related to the retarded body weight development of the offspring.
7) The NOAEL for reproductive performance and fertility was 1500 ppm, equivalent to an average test article consumption of 142/176 and 152/183 mg/kg/day in F 0 /F 1 parent males and females, respectively. Based on reduced body weight gain and food consumption, hypochromic microcytic anemia and centrilobular hepatocellular hypertrophy, the NOAEL for general toxicity was 500 ppm in F 0 and F 1 parent males and females, equivalent to an average test article consumption of approximately 54 mg/kg/day, respectively. Based on retarded growth, delayed sexual maturation and reduced organ weights, the NOAEL for developmental toxicity was 500 and 100 ppm (approximately 54 and 11 mg/kg/day) for F 1 and F 2 progeny, respectively.
Teratogenicity studies were performed in rats and rabbits. The results of these studies are summarised in Table 6 . In the rat teratogenicity study, maternal toxicity was observed at 240 mg/kg: 1 dam died on day 10 post conception (p.c.), transient salivation was noted on days 16-19 p.c., and body weight gain and food consumption were reduced during treatment. Osmotic minipumps containing 5-bromo-2Ј-deoxyuridine (BrdU) were implanted subcutaneously prior to sacrifice and S-phase response was evaluated.
b)
On study day 7, 0.5 ml (1 mCi) of radioactive 125 I was injected. Six hours later and two-and-a-half minutes prior to sacrifice, groups received either potassium perchloride dissolved in saline (10 mg/kg) or saline. There were no treatment-related effects on foetuses. The NOAELs for maternal toxicity and prenatal development toxicity in rats were 120 and 240 mg/kg/day, respectively. In the rabbit teratogenicity study, maternal toxicity was observed at 50 mg/kg: reduced food consumption and body weight loss were noted on days 6-9 p.c. There were no treatment-related effects on foetuses. The NOAELs for maternal toxicity and prenatal development toxicity in rabbits were 15 and 50 mg/kg/day, respectively.
Genotoxicity
Potential mutagenicity was assessed with bacterial reverse mutation tests using Salmonella typhimurium TA1535, TA100, TA1537, and TA98 strains and Escherichia coli WP2 uvrA strain, an in vitro mammalian chromosome aberration test with Chinese hamster V79 cells, an in vitro mammalian cell gene mutation test (hypoxanthin-guanidine phosphoribosyl transferase locus in Chinese hamster ovary cells), an unscheduled DNA synthesis test with rat liver cells in vitro, and a mammalian micronucleus test with male NMRI mice. The results of these studies are summarised in Table 7 . Orysastrobin technical induced a slight but statistically significant increase in structurally aberrant metaphases (gap inclusive or exclusive) either with or without a metabolic activation system in the in vitro mammalian chromosome aberration test with Chinese hamster V79 cells. The results of all other mutagenicity tests were negative. In the absence of chromosome damage in the in vivo study and the lack of any mutagenic potential, the results of the in vitro chromosome aberration study are considered to be not relevant to human risk assessment. Thus, overall, the compound was assessed to be not genotoxic.
Effects of Vital Functions
Effects on vital functions were evaluated with rats and mice at single dose levels of up to 2000 mg/kg. The results of these studies are summarised in Table 8 . Mortality was observed in both species at 2000 mg/kg, associated with decreased respiration, decreased locomotor activities and ataxic gait in mice, and with stagnant growth and hypothermia in rats. No effects on blood pressure, heart rate, pupil size and grip strength were observed in rats at 2000 mg/kg. Charcoal propulsion activity in the small intestine was not affected in mice at 2000 mg/kg. Significant sub-lethal effects were a prolongation of hexobarbital-induced sleeping time in mice at 128 mg/kg, and a decreased urine volume in rats at 320 mg/kg.
Conclusions
Using the EU criteria for classification of a substance as a result of acute lethality, orysastrobin technical is classified as harmful if swallowed and toxic by inhalation; however, general pharmacology studies (conducted at levels of up to 2000 mg/kg) showed that the actual risk of acute poisoning is low. The compound caused no skin or eye irritation or skin sensitisation. In repeated dose toxicity experiments, orysastrobin technical showed potential to cause iron-deficiency anemia (in rats and mice) and hepatocellular hypertrophy associated with the induction of thyroxine-glucuronyltranferase activity (in rats), which leads to enhanced thyroxine (T 4 ) turnover. Secondary adaptive changes in the duodenal mucosa (increased proliferation of the epithelium to increase iron absorption) and thyroid (increased proliferation of follicular cells to increase thyroid hormone synthesis) eventually resulted in an increased tumor incidence in the duodenum of rats and mice, and in the thyroid of male rats in carcinogenicity experiments; however, the primary effects as well as the adaptive secondary changes in the duodenum and thyroid were shown to be reversible and also showed a clear NOAEL of 100 ppm in the diet. Thus, in view of the reversible mechanism of action with a clear threshold dose and the absence of mutagenic potential in vivo, and the well-established excessive sensitivity of rats (compared to humans) to TSH elevation, orysastrobin technical is not considered to present a carcinogenic risk to humans. The NOAELs for reproductive performance and fertility, and pre-and post-natal development were generally higher than those in general toxicity studies. The acceptable daily intake (ADI) should be based on a NOAEL of 100 ppm in the diet in combined chronic toxicity/carcinogenicity studies in 
